Immuneonco Biopharmaceuticals (shanghai) Inc.
Clinical trials sponsored by Immuneonco Biopharmaceuticals (shanghai) Inc., explained in plain language.
-
New drug aims to stop IgG4 disease relapses without Long-Term steroids
Disease control Not yet recruitingThis study tests a drug called IMM0306 in 125 people with IgG4-related disease, a condition where the immune system attacks organs causing swelling and damage. The goal is to see if IMM0306 can prevent disease flare-ups and allow patients to safely stop taking steroids. Participa…
Phase: PHASE2, PHASE3 • Sponsor: ImmuneOnco Biopharmaceuticals (Shanghai) Inc. • Aim: Disease control
Last updated Jun 15, 2026 18:56 UTC
-
New hope for hard-to-treat lymphoma: experimental combo enters final testing phase
Disease control Not yet recruitingThis study tests whether adding the experimental drug IMM0306 to the standard drug lenalidomide helps people with relapsed or refractory follicular lymphoma. About 198 adults whose cancer has not responded to at least two prior treatments will be randomly assigned to receive eith…
Phase: PHASE3 • Sponsor: ImmuneOnco Biopharmaceuticals (Shanghai) Inc. • Aim: Disease control
Last updated Jun 15, 2026 18:55 UTC
-
New drug duo targets hard-to-treat cancers in early trial
Disease control Not yet recruitingThis early-phase study tests two experimental drugs, IMM2510 and IMM01, given together to people with advanced solid tumors that have not responded to at least one prior treatment. The goal is to find a safe dose and see if the combination can shrink tumors or slow their growth. …
Phase: PHASE1, PHASE2 • Sponsor: ImmuneOnco Biopharmaceuticals (Shanghai) Inc. • Aim: Disease control
Last updated Jun 15, 2026 18:54 UTC